- Home
- MGTX vs XNCR Comparison
MGTX vs XNCR Comparison
Compare MGTX & XNCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MGTX
- XNCR
- Stock Information
- Founded
- MGTX 2015
- XNCR 1997
- Country
- MGTX United States
- XNCR United States
- Employees
- MGTX N/A
- XNCR N/A
- Industry
- MGTX Biotechnology: Biological Products (No Diagnostic Substances)
- XNCR Biotechnology: Pharmaceutical Preparations
- Sector
- MGTX Health Care
- XNCR Health Care
- Exchange
- MGTX Nasdaq
- XNCR Nasdaq
- Market Cap
- MGTX 670.2M
- XNCR 547.8M
- IPO Year
- MGTX N/A
- XNCR 2013
- Fundamental
- Price
- MGTX $8.76
- XNCR $13.03
- Analyst Decision
- MGTX Strong Buy
- XNCR Buy
- Analyst Count
- MGTX 2
- XNCR 11
- Target Price
- MGTX $24.00
- XNCR $22.20
- AVG Volume (30 Days)
- MGTX 378.1K
- XNCR 1.3M
- Earning Date
- MGTX 11-12-2025
- XNCR 11-05-2025
- Dividend Yield
- MGTX N/A
- XNCR N/A
- EPS Growth
- MGTX N/A
- XNCR N/A
- EPS
- MGTX N/A
- XNCR N/A
- Revenue
- MGTX $37,917,000.00
- XNCR $146,929,000.00
- Revenue This Year
- MGTX $144.79
- XNCR $23.31
- Revenue Next Year
- MGTX $168.58
- XNCR N/A
- P/E Ratio
- MGTX N/A
- XNCR N/A
- Revenue Growth
- MGTX 366.84
- XNCR N/A
- 52 Week Low
- MGTX $3.97
- XNCR $6.92
- 52 Week High
- MGTX $8.98
- XNCR $27.24
- Technical
- Relative Strength Index (RSI)
- MGTX 67.02
- XNCR 86.24
- Support Level
- MGTX $8.20
- XNCR $11.36
- Resistance Level
- MGTX $8.68
- XNCR $12.63
- Average True Range (ATR)
- MGTX 0.41
- XNCR 0.59
- MACD
- MGTX 0.05
- XNCR 0.13
- Stochastic Oscillator
- MGTX 87.54
- XNCR 98.79
About MGTX MeiraGTx Holdings plc
MeiraGTx Holdings PLC is a clinical-stage gene therapy company. It focuses on the eye, salivary gland, and central nervous system disorders. The company's pipeline products include AAV-CNGB3, AAV-CNGA3 and AAV-RPGR, and others. Geographically, it operates in the United States, the United Kingdom, and European Union.
About XNCR Xencor Inc.
Xencor Inc a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab, and XmAb657. The group earns its revenue from collaboration agreements, product licensing agreements, and technology licensing agreements.